hotspot -WSS

hotspot

author：knowledge 2025-10-01 18:44:57 - browse：649

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： The system is set up to fail children with medical complexity

WSS

Xenotransplantation trials will require adjusting expectations, experts say

Bispecific antibodies are next new thing in cancer immunotherapy

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

My daughter's legacy lives on through her writing, phage therapy

Biden administration plans revamp of organ transplant system

Eli Lilly’s Mounjaro succeeds in second weight

hotspot

hotspot

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

Moderna says combo Covid

In Memoriam: Notable people who died in 2023

Bispecific antibodies are next new thing in cancer immunotherapy

Walensky prepares to leave CDC — and Congress — behind

Inside the rise of 'mukbang' eating videos

Medical records are filled with copy

ALS patient reclaims some autonomy thanks to wearable 'robot'

As demand for Covid shots wanes, Moderna seeks its next success

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

knowledge

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Eli Lilly’s Mounjaro succeeds in second weight

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

NIH tests clinical research in primary care with $30 million program

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

How faith leaders like me can help address America's obesity epidemic

leisure time

focus

hotspot

hotspot